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The metabolism and distribution of C- and S-CS was examined
in 1-, 5-, 10-, 20-, 30-, and 40-day-old rats. During a 3-hr period
following an ip dose of ‘C-CS, 58-83% of the dose was expired as
Cs2 and 4-9% was metabolized to expired CO depending on age.
Thirty- and forty-day-old rats metabolized significantly more CS to
CO2 and expired significantly less CS2 than 1- through 20-day-old
rats. At the end of the measured expiration period, only biotransfor-
mation products of CS2, which were in part covalently bound, re-
mained in tissues from rats of all ages. Tissue levels of S-CS2-
derived radioactivfty exceeded levels of 14C-CS2-derived radioactiv-
ity indicating that sulfur metabolites free from the carbon atom of
CS2 were formed In rats as young as 1 day of age. The S-CS-
derived radioactivity per g of tissue and thus S covalently bound
to tissue protein was significantly higher in 1- through 20-day-old
rats than in 30- and 40-day-old rats. Twenty-four hr after dosing, up
to 13 times more MS-labeled metabolites were covalently bound In
organs from 1-day-old rats than In sImIlar organs from 40-day-old
rats. The results showed that elimination of the biotransformation
products of CS2, In particular the covalently binding sulfur metabo-
Iftes, was prolonged in newborn rats In comparison to 40-day-old
rats.
The mechanisms of toxicity of the volatile solvent carbon
disulfide (CS2) are not clearly understood, but the toxicity may
be a consequence ofCS2 biotransformation (1). The biotransfor-
mation of CS2 has been studied extensively in adult animals (1-
5). CS2 has been shown to be metabolized in adult rats by the
hepatic mixed-function oxidase system to the more toxic metab-
olites, carbonyl sulfide (COS) (I, 3) and an electrophilic sulfur
metabolite (1, 3, 4). COS has been shown to be further metabo-
lized to CO2 by a cytosolic carbonic anhydrase to hydrogen
sulfide (6, 7). Inhibition of the hepatic mixed-function oxidase
system has been observed after CS2 exposure in vivo (8, 9) and
after in vitro incubation of hepatic microsomes with CS2 (1, 3,
4, 9). This inhibition is due to CS2 metabolism by the monoox-
ygenase system and appears to be a result ofthe covalent binding
of the electrophilic sulfur metabolite ( 1 , 3, 4, 9).
Previous investigations with 1-, 5-, 10-, 20-, 30-, and 40-day-
old rats have demonstrated that CS2 is metabolized to a cova-
lently binding sulfur metabolite by hepatic microsomes from rats
as young as 1 day ofage (10). The rate ofthis metabolism varied
with age and was lowest with microsomes from newborn rats.
Concomitant with the in vitro covalent binding, decreases in the
activity ofthe monooxygenase system were observed. In addition,
it has been shown that following exposure of rats of different
ages to CS2, there were declines in the activity of the hepatic
mixed-function oxidase system in 5- through 40-day-old rats but
not in 1-day-old rats (10) suggesting that CS2 is also metabolized
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in vivo by rats older than 1 day ofage. Despite the possibly lower
metabolism of CS2 to the toxic electrophilic sulfur metabolite in
1-day-old rats, the LDo value ofCS2 has been shown to be lower
in 1-day-old rats than in older rats. As a means of investigating
possible mechanisms for the enhanced sensitivity ofthe newborn
to CS2, the present study examines age differences in the in vivo
metabolism, tissue distribution, and elimination of I4C.. and “5-
labeled CS2 in rats.
Materials and Methods
Materials. 35SCS2 (13.6 mCi/mmol) and ‘4C-CS2 (56 mCi/mmol)
were supplied by the Amersham Corp. (Arlington Heights, IL). Unlabeled
CS2 was purchased from Fisher Scientific Co. (Fair Lawn, NJ). The
labeled and unlabeled CS2 were determined to be authentic and pure by
gas chromatography. Omnifluor was from New England Nuclear (Bos-
ton, MA) and Soluene-350 was a product of Packard Instrument Co.
(Downers Grove, IL). Liquiscint was supplied by National Diagnostics
(Somerville, NJ). Authentic COS and hydrogen sulfide (H2S) were from
Scientific Gas Products Inc., (South Plainfield, NJ).
Animals. Sprague-Dawley rats bred and raised in the Animal Resource
Center at East Carolina University were used for experimentation at 1,
5, 10, 20, 30, and 40 days of age. Animal housing has been previously
described (10). One-, five- and ten-day-old rats were unselected as to sex.
With older rats, only males were used.
Distribution and Covalent Binding ofRadiolabeled #{128}S.S-CS or ‘4C-
CS2 (19 mg/kg, 15 MCi/kg) was administered to rats of different ages in
a single ip dose in corn oil (5 ml/kg). This dose was chosen because it
was sublethal for rats of all ages (10), and previous investigators had
found this dose suitable for in vivo metabolism studies (2). Suckling rats
were housed with their mothers until death. At 1, 3, 6, 12, or 24 hr after
injection, rats were etherized, blood samples were taken from the de-
scending aorta with a heparinized syringe, and plasma was obtained by
centrifugation. Liver, lung, kidney, brain, heart, and spleen were removed
and lightly rinsed with 1.15% KC1 (from a squirt bottle) in order to
quickly remove any blood from the outside surface of the organ which
may have collected on the organ during surgery. The tissues were then
promptly blotted and weighed. Plasma (0.05-0.3 ml) and tissue (50-200
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Soluene-350. With 1-, 5-, and 10-day-old rats, often a whole organ was
used as a sample and two to three spleens from 1- or 5-day-old rats were
pooled as one tissue sample. Ten ml of Onmifluor scintillation mixture
(16 g ofOmnifluor in 4 liters oftoluene) were added to solubilized tissue,
and radioactivity of the tissue samples was determined by liquid scintil-
lation counting using a Beckman LS-9000 with external standardization.
The “S- and ‘4C-CS2 equivalents were determined by the following
method. Three 25-al samples of the “S. or ‘4C-CS injection were
counted, and the mean dpm was divided by the amount of CS in the
sample (95 zg). The counts in each tissue sample were then divided by
this standard value to yield equivalents.
After the tissue samples had been taken, the remaining tissue from
each organ was homogenized separately in 3 volumes of distilled water
using a Teflon-glass Potter Elvehjem homogenizer (20 strokes). With 1-
through 10-day-old rats, organs from an additional three to four identi-
cally treated rats were homogenized with any remaining tissue from
similar organs. There were at least three pools of tissue from different
groups ofrats (of the same age) for each organ.
Tissue homogenate was precipitated with an equal volume of4 N HO
and washed exhaustively with methanol:ether (3: 1, v/v) containing un-
labeled CS2 (102 M) until no radioactivity could be extracted into the
wash solvent. The pellet was dried at 50#{176}Cand solubilized in 1 N NaOH
(1 ml). Samples were taken for protein determination by a modification
of the biuret method (10, 1 1), and the remainder was pipetted into
scintillation vials. Ten ml ofLiquiscint were added and radioactivity was
counted; results were expressed as ng of S- or ‘4C-CS2 equivalents
covalently bound/mg of tissue protein.
In vivo Metabolism Studies. Ratswere dosed with 4C-CS2 as described
above and placed immediately in a respiration-metabolism chamber
maintained at 33#{176}C(12) with an incandescent-infrared heat lamp. While
older rats were placed in the chamber singly, two or three younger rats
(1- through 10-day-old) were placed in the chamber in order to ensure
that adequate amounts of CS2 and CS2 metabolites would be expired.
The expired air was drawn through a series of traps with the aid of a
vacuum pump at a rate of 1 liter/mm. The first trap contained 200 ml
of 1 N NaOH to trap ‘4C-CO2, and the second and third traps contained
100 and 75 ml, respectively, of 95% ethanol/diethylamine (1:1, v/v) to
trap ‘4C-CS2 and 4C-COS (2). Expired air was collected for 3 hr from
the time of injection. The contents of the second and third traps were
analyzed by gas chromatography for CS2 and COS as described below.
Radioactivity in the traps was determined by liquid scintillation counting
using Liquiscint. Rats were killed at the end of the 3-hr period, and
tissues were used for distribution studies. Since tissue levels of radioac-
tivity in animals housed in the metabolism chambers were the same as
levels in animals housed in “shoe-box” cages, we concluded that placing
the rats in the chambers did not significantly alter the distribution of
CS2.
In Vitro Metabolism of  to COS. Hepatic microsomes were
isolated from rats as previously described (10) and resuspended in 0.05
M Hepes’ buffer, pH 7.8. Microsomal incubations with CS2 (2 x l0
M) were carried out at 37#{176}Cas described previously (10). The reaction
mixture contained 10 mg ofmicrosomal protein, an NADPH-generating
system, and butylated hydroxytoluene in a total volume of 5 ml of 0.05
M Hepes buffer, pH 7.8. Control incubations were run in the absence of
the NADPH-generating system. After a 10-mm incubation, the reaction
was terminated by the addition of 2 ml of 20% trichloroacetic acid, and
the flasks were heated to 60C. The amount of COS in three 200-l
samples of the head space from each flask was measured by gas chro-
matography as described below, and the mean value was determined.
The total amount of COS in each flask was calculated from the total
volume ofthe flask minus the volume ofthe liquid. The amount of COS
dissolved in the liquid has been reported to be negligible (3).
Gas Chromatography. Gas chromatographic analysis was carried out
with a Varian gas chromatograph (Varian Instruments Co., Model 3700).
By using the method of Thornsberry (13) modified to include a flame
‘Abbreviation used is: Hepes, 4-(2-hydroxyethy-1-piperazineethanesulfonic
photometric detector, CS, COS, and H2S were detectable down to
picomolar levels. The amount of COS was quantitated based on a
standard curve ofauthentic COS.
Statistics. Statistical analysis was performed by the single factor analy-
sis of variance with level of significance chosen as p < 0.05. Post hoc
comparison was performed by the SchefI test. p < 0.1 was designated
as the level of significance. However, comparisons between 1- and 40-
day-old rats in figs. 5 and 6 and between “S- and ‘4C-CS levels in similar
tissues were performed by Student’s t test with p < 0.05 chosen as the
level of significance.
Results
During a 3-hr period following ‘4C-CS2 exposure, between
58% and 83% of the dose of 14C-CS2 was expired depending on
rat age (fig. 1, lower panel). The 3-hr time period was chosen
because preliminary studies showed that the expiration ofCS2 in
rats ofdifferent ages was complete at this time. While the amount
ofCS2 expired did not differ significantly in rats from 1-20 days
of age, from 20-40 days of age a significant decline in CS2
expiration was observed. In contrast, significantly more of the
dose of ‘4C-CS2 was expired as 14C-C02 in 30- and 40-day-old
rats than in the younger rats examined (fig. 1, upper panel). The
amount of CO2 expired nearly doubled as rats matured from 20
to 30 days ofage. The total per cent ofthe dose expired (‘4C-CS2
plus ‘4C-C02) was 80-87% in 1-, 5-, 10-, and 20-day-old rats,
while 75% and 65% ofthe total dose was expired in 30- and 40-
day-old rats, respectively.
COS has been previously observed in the expired air of adult
rats administered CS2 (2). Since in the present study COS was
not detected in the expired air of rats of any age given CS2, the
ability of isolated hepatic microsomes from rats of various ages
to metabolize CS2 to COS was examined. COS was detected in
the head space of incubation flasks after incubation of hepatic
microsomes from rats of all ages with CS2 in the presence of an
NADPH-generating system (fig. 2). The rate of COS production
was significantly lower in incubations containing microsomes
50
1 5 10 20 30 40
AGE (lys)
FIG. 1 . The percentage ofihe dose of ‘4C-CS2 expired as ‘4C-CS2 and
‘4c-cs2.
The expired air from rats of different ages was collected for a 3-hr
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FIG. 2. The amount of COS formed by hepatic microsomes from rats of
different ages.
Hepatic microsomes were incubated with CS2 (2 x l0 M) in the
presence of an NADPH-generating system. In the absence of the gener-
ating system, no COS was detected. Each value represents the mean ±
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FIG. 3. Tissue levels of 355-C52 equivalents (panel A) and ‘4C-C52
equivalents (panel B) in rats ofdifferent ages.
Rats were killed 3 hr after dosing with radiolabeled CS2. The values
are the mean ± SE of3-lO rats.
from 1-day-old rats than in incubations containing microsomes
from older rats. COS production increased as rats matured from
1 to 20 days of age and decreased as rats matured from 20 to 40
days ofage. As was previously observed with the in vitro covalent
binding of the electrophilic sulfur metabolite of CS2 to hepatic
microsomes (10), the in vitro rate of COS formation was highest
with microsomes from 20-day-old rats.
At the end of the measured expiration period, 1-2% of the
dose of ‘4C-CS2 was retained in the liver, lung, kidney, brain,
spleen, and heart from the rats of different ages. Following an
equivalent dosage of 35S-CS2, 4-6% of the dose of 35S-C52 re-
mained in these organs from 1- through 20-day-old rats, while
1-2% remained in 30- and 40-day-old rats. Within each age
group, the 35S-CS2-derived radioactivity in plasma was signifi-
cantly higher than 355-CS2-derived radioactivity in all organs
examined, except the kidney in 20-day-old rats (fig. 3A). In 1-
through 20-day-old rats, the kidney generally contained the most
radioactivity per g of tissue among the organs examined. How-
ever, in 30- and 40-day-old rats, the liver and kidney had the
same level of radioactivity per g of tissue. Within each age group,
the 35S-CS2-derived radioactivity per g oflung, spleen, and heart
was the same or less than the level of radioactivity per g of liver
(data not shown for all organs). The brain contained significantly
lower levels of “S radioactivity (per g of tissue) than all other
tissues examined within each age group. Levels of 35S-CS2 equiv-
alents were 2-7 times higher in tissues from I- through 20-day-
old rats than in identical tissues from 30- and 40-day-old rats.
The distribution of ‘4C-C52 equivalents was distinct from the
distribution of 35S-CS2 equivalents (compare A and B of fig. 3).
Levels of ‘4C-CS2-derived radioactivity were highest in liver and
kidney and exceeded the level of radioactivity per ml of plasma
within each age group (fig. 3B). The radioactivity per g of lung,
brain, spleen, and heart was the same or less than the radioactiv-
ity per ml of plasma (data not shown for all organs). The brain
had significantly lower levels of radioactivity per g than all other
tissues examined. Plasma levels of 14C-CS2 equivalents were not
significantly different among rats of different ages. However,
some age differences in the tissue levels of ‘4C-CS2-derived radio-
activity were observed. The levels of 14C-CS2 equivalents in most
A organs (except brain) from 1-day-old rats were, in general, sig-
nificantly higher than the levels in identical organs from older
rats.
Comparison between 355 and ‘4C levels showed that levels of
35S-CS2 equivalents were significantly higher than levels of 14C-
CS2 equivalents in identical tissues within each age group (with
the exception of the liver levels of 4C and 355 radioactivity in
30-day-old rats which were not significantly different). In addi-
tion, the differences between 35S and 14C levels were greater in 1-
through 20-day-old rats than in 30- and 40-day-old rats (compare
panels A and B in fig. 3). For example, in 1- through 20-day-old
rats, 14-23 times more 355 than ‘4C-CS2-derived radioactivity
was in the plasma. However, in 30- and 40-day-old rats, 2-6
times more 355 than ‘4C-CS2-derived radioactivity was found in
B the plasma.
Three hr after CS2 administration, no CS2 was detected in any
of the organs (liver, lung, kidney, brain, spleen, and heart) from
rats of all ages examined since treatment of tissue homogenates
with heat and nitrogen gas via the method of McKenna and
Distefano (14) did not decrease the amount of ‘4C-CS2-derived
radioactivity in the tissues (data not shown). In the liver of rats
of all ages examined, 58-100% of the total 4C-CS2 equivalents
per mg of tissue protein was resistant to acid hydrolysis, while
the remaining radioactivity was acid-labile and thus may have
been dithiocarbamate derivatives  of CS2 (14). In
(RNH-C-SH)
addition, when the same experiment was run on tissues from
rats given 35S-CS2 and killed after 6 hr, no volatile 35S-CS2 or 355
CS2-derived radioactivity was found. Ofthe total 35S-CS2-derived
radioactivity in the liver at 6 hr, approximately 30-50% was in
an acid-resistant, covalently bound form, and the remaining 355-
CS2-derived radioactivity was acid-labile.
High levels ofcovalently bound 35S-CS2 equivalents were found
in tissues from 1- through 20-day-old rats in comparison to older
rats (fig. 4A). Between 2 and 7 times more 355-CS2 equivalents
were covalently bound per mg of protein in liver, kidney, and
brain from 1- through 20-day-old rats than in identical organs
from 30- and 40-day-old rats. In addition, only in 1- through 20-
day-old rats did the covalent binding of 35S-CS2 equivalents
significantly exceed the covalent binding ‘4C-CS2 equivalents in
comparable organs (compare panels A and B in fig. 4).
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FIG. 4. The covalent binding of 35S-CS2 equivalents (panel A) and ‘4C-
CS2 equivalents (panel B) in tissues from rats of different ages.
Rats were killed 3 hr after dosing with radiolabeled CS2. The values
are the mean ± SE of three to six rats or different groups of rats as
described under Materials and Methods.
TIME (hours)
FIG. 5. Plasma and liver levels of “S- and ‘4C-C52 equivalents in 1-
day-old rats (panelA) and 40-day-old rats (panel B).
35S-CS2 equivalents in plasma (0) and in liver () and ‘4C-CS2 equiv-
alents in plasma (#{149})and liver (A) were measured in 1- and 40-day-old
rats at various times after dosing with radiolabeled CS. The values are
the means ± SE of3-l0 rats.
examined in 1-day-old newborn rats and the oldest group of rats
of 40 days of age over a 24-hr period (fig. 5, A and B). Elimination
of 35S- and ‘4C-CS2 equivalents from all organs examined gen-
erally paralleled the elimination from the liver. In 40-day-old
rats, peak levels of 355-CS2 equivalents in liver and plasma were
A observed at 1 hr and had declined by 6 hr after dosing (fig. SB).
While levels of ‘4C-CS2 equivalents in the liver declined from 1-
6 hr, levels of ‘4C-CS2 equivalents in the plasma did not change
significantly over a 24-hr period. Liver and plasma levels of 35S-
CS2 equivalents in 40-day-old rats exceed 14C-CS2 equivalents
for up to 3 and 6 hr, respectively.
In 1-day-old rats, 35S-CS2 equivalents in liver and plasma were
significantly higher than the 14C-CS2 equivalents over the entire
24-hr period (fig. 5A). Significant declines in the levels of 355W
CS2-derived radioactivity were not observed until 12 hr after 355W
CS2 administration. Comparison of 35S-CS2 levels between 1-
B and 40-day-old rats showed that up to 7 times more 35S-CS2
equivalents were in plasma and liver from 1-day-old rats at all
times later than 1 hr(compare panels A and B in fig. 5). However,
plasma levels of ‘4C-C52 equivalents were the same in 1-day-old
rats as in 40-day-old rats, and liver levels of ‘4C-CS2 equivalents
.- were not more than 3 times higher in 1-day-old rats over the 24-
hr period.
Twenty-four hr after CS2 administration, significantly more
covalently bound 35S-CS2 equivalents were found in organs from
1-day-old rats than in identical organs from 40-day-old rats (fig.
6A). Three, eight, and thirteen times more 35S-CS2 equivalents
remained covalently bound in liver, kidney, and brain from 1-
day-old rats than from 40-day-old rats. In addition, 2-4 times
A more 355 than 14C-CS2 equivalents was found in liver, kidney,
and brain from 1-day-old rats (compare panels A and B in fig.
6). However, in 40-day-old rats, 355 levels were the same or not
more than twice the levels of ‘4C-CS2 equivalents. Hence, the
magnitude of the differences between the 355 and ‘4C-C52-
derived radioactivity covalently bound in comparable tissues was
much less in 40-day-old rats than in 1-day-old rats.
Discussion
It is widely recognized that the metabolism and toxicity of
many xenobiotics vary with age. In the present study, we inves-
tigated the metabolism and distribution ofCS2 in rats of different
ages which have been shown to differ in sensitivity to CS2 toxicity
(10). CS2 was shown to be biotransformed in vivo to CO2 in rats
as young as 1 day of age. While the amount of CS2 biotrans-
formed to CO2 was not significantly different among 1- through
20-day-old rats, it increased as rats matured to 30 and 40 days
of age. Expiration of CO2 has been reported to be a measure of
the hepatic mixed-function oxidase metabolism of CS2 and the
amount of CO2 exhaled directly related to the monooxygenase
activity at the time ofCS2 administration (2, 5). Thus, the results
from this study suggest that the capacity for the hepatic mixed-
function oxidase metabolism ofCS2 in vivo is evident as early as
1 day of age and increases most greatly between 20 and 30 days
ofage in the rat.
Data from in vitro studies with hepatic microsomes confirmed
that CS2 was metabolized by the hepatic monooxygenase system
in rats as young as 1 day of age. In contrast to the results from
the in vivo studies, the results from the in vitro studies showed
that the hepatic monooxygenase metabolism of CS2 to COS was
highest in 20-day-old rats. The discrepancy between the in vitro
and apparent in vivo monooxygenase activities could be due to
many factors. Unlike in vitro, the in vivo metabolism may be
influenced by additional factors which may vary with age such
as availability of cofactors for the monooxygenase system, the
distribution and binding of the xenobiotic to the endoplasmic
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FIG. 6. The covalent binding of “S-CS2 equivalents (pane/A) and ‘4C-
CS2 equivalents (panel B) in tissuesfrom 1- and 40-day-old rats.
Rats were killed 24 hr after dosing with radiolabeled CS2. The values
are the means ± SE of three to six rats or different groups of rats as
described under Materials and Methods.
cytochrome P-450 including phopholipids and steroids which
may hinder xenobiotic metabolism in vivo (15).
The results from in vivo metabolism and expiration studies
have suggested that an indirect relationship exists between the
biotransformation of CS2 to CO2 and expiration of CS2. Among
the rats of different ages, the greater the biotransformation of
CS2 to C02, the less CS2 expired. In addition, an enhanced
metabolism appeared to result in a diminished recovery of the
total expired dose of CS2 (CS2 plus C02). This indirect relation-
ship between CS2 metabolism and recovery of the expired dose
has also been observed with phenobarbital-pretreated adult rats
in comparison to non-pretreated adult rats (2, 5). Thus, it ap-
peared that an enhanced metabolism of CS2 hinders the expira-
tion ofCS2 and may facilitate the retention ofCS2 as metabolites
which require excretion by alternate pathways.
Expiration of CS2 was an important route of excretion of the
parent compound since, during a 3-hr period following CS2
administration, 58% to 83% of the dose was expired. When the
expiration of CS2 was complete, no CS2 could be detected in
tissues. However, biotransformation products which were either
acid-labile or resistant to acid hydrolysis were found. Levels of
35S-CS2 equivalents exceeded the levels of ‘4C-CS2 equivalents
(particularly in 1- through 20-day-old rats) indicating that sulfur-
containing metabolites which were structurally free from the
A carbon atom of CS2 were formed. The difference in the amount
of 14C- and 35S-CS2 equivalents may have been due, in part, to
the biotransformation of CS to expired CO2. Examination of
the contents in the exhaled air showed that 4-9% of the dose of
I4C-cS2 was exhaled as ‘4C-C02 in rats, depending on age.
However, no sulfur-containing metabolites were found in the
expired air. Thus, 4-9% more 355- than ‘4C-CS2-derived radio-
activity may have been retained in the tissues as a consequence
of the differences in exhalation alone. The data indicated that
via metabolism of CS2 to CO2 by the hepatic mixed-function
oxidase system, which was observed as early as 1 day of age in
rats, the carbon moiety of CS2 was freed from the sulfur portion
of CS2 and expired leaving sulfur-containing metabolites of CS2
in the tissues. Despite the lower metabolism ofCS2 in 1- through
20-day-old rats, more 35S-CS2-derived radioactivity remained in
1- through 20-day-old rats than in 30- and 40-day-old rats
suggesting that excretion of sulfur-containing metabolites of CS2
was prolonged in younger rats. The 24-hr distribution of radio-
labeled CS2 in 1- and 40-day-old rats clearly showed that eimi-
nation of sulfur-containing metabolites from the tissues was
much slower in 1-day-old rats than in 40-day-old rats.
The metabolites carrying only the sulfur atom of CS2 were
distinct from those carrying the carbon atom ofCS2 as shown by
differences in the distribution of 355 and 14C-CS2-derived radio-
activity. Both ‘4C- and 35S-CS2-derived metabolites, however,
persisted in tissues for at least 24 hr in an acid-resistant form
covalently bound to tissue protein (fig. 6). The covalently bound
metabolites carrying the carbon atom of CS2 may have been
isothiocyanates (R-N=C=S) and/or isocyanates (R-N=C=O) (3,
16). The covalently bound 35S may have been due to the electro-
philic sulfur metabolite ( 1 , 3). However, it appeared unlikely that
the elevated levels of acid-resistant covalently bound sulfur was
due only to the binding of the electrophilic sulfur metabolite for
the following reasons. One-day-old rats apparently metabolize
significantlyless CS2 in vivo than 40-day-old rats(fig. 1); however,
1-day-old rats show significantly higher levels of covalently
bound 35S-CS2 equivalents in vivo (figs. 4 and 6). In addition, the
covalent binding ofsulfur metabolites was lower in the liver than
in extrahepatic tissues despite the generally higher monooxygen-
ase activity in the liver(17). Generation ofthe electrophilic sulfur
atom in the liver could not be responsible for high covalent
binding in extrahepatic tissues since the electrophiic sulfur atom,
owing to its reactivity, would bind at the site where it was formed
(18).
Other possible sulfur-containing metabolites of CS2 such as
sulfate, thiosulfate, hydrosulfide anion (from hydrogen sulfide),
and sulfite may also be responsible for the observed acid-resistant
covalently bound pool and the acid-labile pool of sulfur metab-
olites. As shown in fig. 7, these sulfur metabolites may have
arisen from the metabolism of COS. Increases in urinary sulfate
have been found in urine of man and animals exposed to CS2
(19, 20). Thiosulfate has been detected in isolated hepatocytes
incubated with COS, and the hydrosulfide anion may arise from
the metabolism of COS to hydrogen sulfide (6). As shown in fig.
7, hydrogen sulfide may also be generated from the decomposi-
tion of dithiocarbamates (16). Although sulfite has not yet been
identified as a metabolite ofCS2, it is a likely intermediate in the
oxidation of hydrogen sulfide to sulfate (21, 22). Thiosulfate,
hydrosulfide, and sulfite have the potential to cleave endogenous
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FIG. 7. Proposedpathways ofCS2 metabolism.
The data indicated that newborn rats have a lower capacity to
excrete these possible sulfur metabolites as shown by high tissue
levels of35S in comparison to 40-day-old rats. This lower capacity
for excretion may have resulted in a higher covalent binding of
sulfur in 1-day-old rats. For example, the low sulfite oxidase
activity in newborn rats (27) may have resulted in higher levels
of sulfite and ultimately higher covalent binding. The increase
in covalently bound sulfur from 3 to 24 hr in many tissues from
1-day-old rats suggested that the covalent binding of sulfur
metabolites occurred gradually as a result of their high tissue
levels for a prolonged period of time.
The toxicological significance of the elevated levels of sulfur
metabolites in 1-day-old rats is uncertain. Since the 24-hr LD
value ofCS2 in 1-day-old rats has been shown to be less than the
value in 40-day-old rats (10), the results ofthe present study may
implicate CS2 biotransformation to sulfur-containing metabolites
as a possible mechanism of CS2 toxicity in newborn rats.
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